Literature DB >> 16553110

Patient with markedly elevated CA 19-9 not associated with malignancy.

Douglas Lowe1, Jeffrey Lee, Robert Schade, Ayaz Chaudhary.   

Abstract

A 66-year-old white male presented with jaundice, pruritus, and a 30-pound weight loss over two months. Physical examination revealed scleral icterus. Laboratory evaluation revealed ALT 161 U/L, AST 290 U/L, alkaline phosphatase 2004 U/L, GGT 2,552 U/L, total bilirubin 10.2 mg/dL, and a carbohydrate antigen 19-9 (CA 19-9) level of 4,374 U/mL. Initial endoscopic retrograde cholangiopancreatography (ERCP) was unsuccessful due to ulceration in the duodenum healed with esomeprazole therapy. Subsequent ERCP showed a possible filling defect in the common bile duct treated with sphincterotomy and balloon sweeping of the common bile duct. Symptoms and jaundice resolved five months after initial presentation with normal labs and studies. While elevated CA 19-9 levels occur in most patients with carcinoma of the pancreas, it can also be elevated in patients with extrapancreatic malignancies and acute cholangitis. This case illustrates the fact that a markedly elevated CA 19-9 can be secondary to causes other than carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16553110     DOI: 10.1097/01.smj.0000202695.97123.2b

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.

Authors:  Gaetano La Greca; Maria Sofia; Rosario Lombardo; Saverio Latteri; Agostino Ricotta; Stefano Puleo; Domenico Russello
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

2.  Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.

Authors:  S L Ong; G Garcea; S C Thomasset; C D Mann; C P Neal; M Abu Amara; A R Dennison; D P Berry
Journal:  J Gastrointest Surg       Date:  2007-11-28       Impact factor: 3.452

3.  CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?

Authors:  M M S Bedi; M D Gandhi; G Jacob; V Lekha; A Venugopal; H Ramesh
Journal:  Indian J Gastroenterol       Date:  2009-06-06

4.  Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.

Authors:  Hae Kyung Lee; Hiun Suk Chae; Jin Soo Kim; Hyung Keun Kim; Young Seok Cho; Sang Young Rho; Jin-Hyoung Kang; Seok Goo Cho; Hong Seok Jang; Kyungja Han
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.